Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients

Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients

This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of a...

Full description

Bibliographic Details
Main Authors: Tomoko Mizushige, Hiroyuki Kobori, Hirofumi Hitomi, Yoko Nishijima, Fumihiro Tomoda, Satoshi Morimoto, Masakazu Kohno, Akira Nishiyama
Format: Article
Language:English
Published: MDPI AG 2016-10-01
Series:International Journal of Molecular Sciences
Subjects:
urinary angiotensinogen
metabolic syndrome
angiotensin receptor blocker
renin-angiotensin system
prognostic marker of albuminuria reduction effects
Online Access:http://www.mdpi.com/1422-0067/17/11/1800

Internet

http://www.mdpi.com/1422-0067/17/11/1800

Similar Items